Clemens, P. R., Mozaffar, T., Schoser, B., Bratkovic, D., Byrne, B. J., Goker-Alpan, O., … Ming, X. (2019). Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial. In Molecular Genetics and Metabolism (Vol. 126, pp. S40–S41). Elsevier BV. https://doi.org/10.1016/j.ymgme.2018.12.084

Clemens, Paula R., Tahseen Mozaffar, Benedikt Schoser, Drago Bratkovic, Barry J. Byrne, Ozlem Goker-Alpan, Mark Roberts, et al. “Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial.” In Molecular Genetics and Metabolism, 126:S40–41. Elsevier BV, 2019. https://doi.org/10.1016/j.ymgme.2018.12.084.

Clemens PR, Mozaffar T, Schoser B, Bratkovic D, Byrne BJ, Goker-Alpan O, et al. Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial. In: Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S40–1.

Clemens, Paula R., et al. “Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial.” Molecular Genetics and Metabolism, vol. 126, no. 2, Elsevier BV, 2019, pp. S40–41. Crossref, doi:10.1016/j.ymgme.2018.12.084.

Clemens PR, Mozaffar T, Schoser B, Bratkovic D, Byrne BJ, Goker-Alpan O, Roberts M, Schwenkreis P, Sivakumar K, van der Ploeg AT, Wright J, Sitaraman S, Barth JA, Lagast H, Kishnani P, Ming X. Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial. Molecular Genetics and Metabolism. Elsevier BV; 2019. p. S40–S41.